{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:52:46Z","timestamp":1740124366299,"version":"3.37.3"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The monitoring of response in chronic myeloid leukemia (<jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>) is of great importance to identify patients failing their treatment in order to adjust <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content> choice and thereby prevent progression to advanced stage disease. Cytogenetic monitoring has a lower sensitivity, is expensive, and requires invasive bone marrow sampling. Nevertheless, chronic myeloid leukemia guidelines continue to recommend performing routine cytogenetic response assessments, even when adequate molecular diagnostics are available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a population\u2010based registry of newly diagnosed <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> patients in the Netherlands, all simultaneous cytogenetic and molecular assessments performed at 3, 6, and 12\u00a0months were identified and response of these matched assessments was classified according to European Leukemia Net (<jats:styled-content style=\"fixed-case\">ELN<\/jats:styled-content>) recommendations. The impact of discrepant cytogenetic and molecular response classifications and course of patients with additional chromosomal abnormalities were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall agreement of 200 matched assessments was 78%. In case of discordant responses, response at 24\u00a0months was consistently better predicted by the molecular outcome. Cytogenetic response assessments provided relevant additional clinical information only in some cases of molecular \u201cwarning.\u201d The development of additional cytogenetic abnormalities was always accompanied with molecular failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We conclude that it is safe to omit routine cytogenetics for response assessment during treatment and to only use molecular monitoring, in order to prevent ambiguous classifications, reduce costs, and reduce the need for invasive bone marrow sampling. Cytogenetic re\u2010assessment should still be performed when molecular response is suboptimal.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13023","type":"journal-article","created":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T02:02:35Z","timestamp":1514599355000},"page":"367-371","source":"Crossref","is-referenced-by-count":6,"title":["Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe"],"prefix":"10.1111","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9470-476X","authenticated-orcid":false,"given":"Inge G.P.","family":"Geelen","sequence":"first","affiliation":[{"name":"Department of Hematology Albert Schweitzer Hospital  Dordrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noortje","family":"Thielen","sequence":"additional","affiliation":[{"name":"Department of Hematology VU University Medical Center  Amsterdam The Netherlands"},{"name":"Department of Internal Medicine Diakonessenhuis  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J.W.M.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Hematology VU University Medical Center  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mels","family":"Hoogendoorn","sequence":"additional","affiliation":[{"name":"Department of Hematology Medical Center Leeuwarden  Leeuwarden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja J.A.","family":"Roosma","sequence":"additional","affiliation":[{"name":"Department of Hematology VU University Medical Center  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.M.","family":"Valk","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus University Medical Center  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto","family":"Visser","sequence":"additional","affiliation":[{"name":"Netherlands Comprehensive Cancer Organisation (IKNL)  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan J.","family":"Cornelissen","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus University Medical Center  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Westerweel","sequence":"additional","affiliation":[{"name":"Department of Hematology Albert Schweitzer Hospital  Dordrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_8_2_1","DOI":"10.1185\/03007995.2013.812034"},{"doi-asserted-by":"publisher","key":"e_1_2_8_3_1","DOI":"10.1185\/03007995.2013.858621"},{"doi-asserted-by":"publisher","key":"e_1_2_8_4_1","DOI":"10.3324\/haematol.2017.175265"},{"doi-asserted-by":"publisher","key":"e_1_2_8_5_1","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_8_6_1","first-page":"260","article-title":"Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression","volume":"88","author":"Marktel S","year":"2003","journal-title":"Haematologica"},{"doi-asserted-by":"publisher","key":"e_1_2_8_7_1","DOI":"10.1182\/blood-2003-02-0371"},{"doi-asserted-by":"publisher","key":"e_1_2_8_8_1","DOI":"10.1002\/cncr.25015"},{"doi-asserted-by":"publisher","key":"e_1_2_8_9_1","DOI":"10.1182\/blood-2016-01-690230"},{"doi-asserted-by":"publisher","key":"e_1_2_8_10_1","DOI":"10.1093\/annonc\/mdx219"},{"key":"e_1_2_8_11_1","first-page":"e299","article-title":"Imatinib\u2010treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6\u00a0month time\u2010points have a reduced probability of subsequent optimal response","volume":"100","author":"Bonifacio M","year":"2015","journal-title":"Haematologica"},{"doi-asserted-by":"publisher","key":"e_1_2_8_12_1","DOI":"10.3324\/haematol.2017.174953"},{"doi-asserted-by":"publisher","key":"e_1_2_8_13_1","DOI":"10.1046\/j.1365-2141.1999.01749.x"},{"doi-asserted-by":"publisher","key":"e_1_2_8_14_1","DOI":"10.1038\/sj.leu.2404139"},{"doi-asserted-by":"publisher","key":"e_1_2_8_15_1","DOI":"10.5858\/arpa.2013-0584-OA"},{"key":"e_1_2_8_16_1","first-page":"49","article-title":"Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy","volume":"89","author":"Lange T","year":"2004","journal-title":"Haematologica"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T21:31:07Z","timestamp":1695504667000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/ejh.13023"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13023","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}